Search Results

Recombinant biopharmaceuticals and vaccines represent a significant class of therapeutics and preventions. While the industry has established efficient platformed processes for the production of monoclonal antibodies at multi-ton scales, the improved precision of therapeutic indications and expanding molecular designs (such as bispecific antibodies, nanobodies, and others) add new challenges for the timely and cost-effective production of emerging therapeutic concepts. This talk will present an integrated approach to biomanufacturing that combines automated end-to-end production and purification along with a fast and engineering-friendly alternative host to enable a flexible platform for next-generation manufacturing. Examples in both biopharmaceuticals and vaccines will be presented.